| (1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methyl-6-triethylsilyloxyheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-one |
骨化三醇CD环14-EPI-杂质 |
1101133-55-4 |
| Nifedipine Impurity J |
硝苯地平杂质J |
114709-68-1 |
| 2-(2-Hydroxyphenyl)-4-methyl-5-thiazolecarboxylic acid ethyl ester |
非布索坦中间体杂质 |
118485-48-6 |
| Febuxostat Impurity 6 |
非布司他杂质6 |
1271738-74-9 |
| OlMesartan Ethyl Ester IMpurity |
奥美沙坦酯乙酯杂质 |
144689-23-6 |
| 4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid |
4-(2-羟异丙基)-2-丙基-1H-咪唑-5-甲酸 |
144690-04-0 |
| OlMesartan interMediate iMpurity II |
咪唑单乙酯杂质II |
144690-07-3 |
| Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate |
2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸乙酯 |
160844-75-7 |
| Linagliptin Impurity H |
利格列汀杂质H |
1646355-34-1 |
| Febuxostat Impurity 130 |
Febuxostat Impurity 130 |
1643131-93-4 |
| Vildagliptin Related Compound F |
维格列汀杂质F |
1789703-36-1 |
| vildagliptin Impurity E |
维格列汀杂质E |
1789703-37-2 |
| Linagliptin Impurity C |
Linagliptin Impurity C |
1791405-13-4 |
| Bromazine Hydrochloride |
BROMODIPHENHYDRAMINE |
1808-12-4 |
| Methanediamine, 1-(2-nitrophenyl)-N,N'-bis[(2-nitrophenyl)methylene]- |
诺氟沙星杂质6 |
126192-88-9 |
| 1,3-Cyclohexanediol, 2-(3-hydroxypropoxy)-4-methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1S)-5-hydroxy-1,5-dimethylhexyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,2R,3R,5Z)- |
1,3-Cyclohexanediol, 2-(3-hydroxypropoxy)-4-methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1S)-5-hydroxy-1,5-dimethylhexyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,2R,3R,5Z)- |
1217549-27-3 |
| ethyl 2-(3,5-diformyl-4-hydroxyphenyl)-4-methylthiazole-5- carboxylate |
非布索坦杂质39 |
2073891-59-3 |
| Linagliptin Impurity JX |
Linagliptin Impurity JX |
2137744-33-1 |
| M-NIFEDIPINE |
4-(间硝基苯基)-2,6-二甲基-1,4-二氢-3,5-吡啶二羧酸二甲酯 |
21881-77-6 |
| NSC 136464 |
间硝苯地平 |
21829-28-7 |
QQ
微信
